@article{5a301c6deb4d4490832143b5a9d75391,
title = "Death in hospital following ICU discharge: insights from the LUNG SAFE study",
abstract = "Background: To determine the frequency of, and factors associated with, death in hospital following ICU discharge to the ward. Methods: The Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE study was an international, multicenter, prospective cohort study of patients with severe respiratory failure, conducted across 459 ICUs from 50 countries globally. This study aimed to understand the frequency and factors associated with death in hospital in patients who survived their ICU stay. We examined outcomes in the subpopulation discharged with no limitations of life sustaining treatments ({\textquoteleft}treatment limitations{\textquoteright}), and the subpopulations with treatment limitations. Results: 2186 (94%) patients with no treatment limitations discharged from ICU survived, while 142 (6%) died in hospital. 118 (61%) of patients with treatment limitations survived while 77 (39%) patients died in hospital. Patients without treatment limitations that died in hospital after ICU discharge were older, more likely to have COPD, immunocompromise or chronic renal failure, less likely to have trauma as a risk factor for ARDS. Patients that died post ICU discharge were less likely to receive neuromuscular blockade, or to receive any adjunctive measure, and had a higher pre- ICU discharge non-pulmonary SOFA score. A similar pattern was seen in patients with treatment limitations that died in hospital following ICU discharge. Conclusions: A significant proportion of patients die in hospital following discharge from ICU, with higher mortality in patients with limitations of life-sustaining treatments in place. Non-survivors had higher systemic illness severity scores at ICU discharge than survivors. Trial Registration: ClinicalTrials.gov NCT02010073.",
keywords = "Acute hypoxemic respiratory failure, Acute respiratory distress syndrome, Hospital survival, ICU discharge, LUNG SAFE",
author = "{the LUNG SAFE Investigators and the ESICM Trials Group} and Fabiana Madotto and Bairbre McNicholas and Emanuele Rezoagli and T{\`a}i Pham and Laffey, {John G.} and Giacomo Bellani and Antonio Pesenti and Laffey, {John G.} and Laurent Brochard and Andres Esteban and Luciano Gattinoni and {van Haren}, Frank and Marco Ranieri and Gordon Rubenfeld and Thompson, {B. Taylor} and Slutsky, {Arthur S.} and Fernando Rios and Faruq, {Mohammad Omar} and T. Sottiaux and P. Depuydt and Lora, {Fredy S.} and Azevedo, {Cesar Cesar} and Eddy Fan and Guillermo Bugedo and Haibo Qiu and Marcos Gonzalez and Juan Silesky and Vladimir Cerny and Jonas Nielsen and Manuel Jibaja and T{\`a}i Pham and Hermann Wrigge and Dimitrios Matamis and Ranero, {Jorge Luis} and Charles Gomersall and Pravin Amin and Hashemian, {S. M.} and Kevin Clarkson and Kiyoyasu Kurahashi and Younsuck Koh and Asisclo Villagomez and Zeggwagh, {Amine Ali} and Heunks, {Leo M.} and Laake, {Jon Henrik} and Waqar Kashif and Jorge Synclair and Palo, {Jose Emmanuel} and {do Vale Fernandes}, Antero and Dorel Sandesc and Aditya Uppalapati",
note = "Funding Information: This research was partially supported by the Italian Ministry of University and Research (MIUR)—Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic) and by a Science Foundation Ireland Future Research Leaders Award to Prof Laffey (16-FRL-3845). This LUNG SAFE Study was supported by the European Society of Intensive Care Medicine (ESICM), Brussels, Belgium, by St Michael{\textquoteright}s Hospital, Toronto, Canada, and by the University of Milan-Bicocca, Monza, Italy. Funding Information: The detailed methods and protocol have been published elsewhere []. In brief, LUNG SAFE was an international, multicentre, prospective cohort study, with a 4-week enrolment window in the winter season []. The study, funded by the European Society of Intensive Care Medicine (ESICM), was endorsed by multiple national societies/networks (Acknowledgements). All participating ICUs obtained ethics committee approval, and either patient consent or ethics committee waiver of consent. National coordinators (Acknowledgements) and site investigators (Acknowledgements) were responsible for obtaining ethics committee approval and for ensuring data integrity and validity. Funding Information: Prof Laffey reports personal fees from consultancy for Baxter and Cala Medical, and funds to his institution from grants from Science Foundation Ireland, the Health Research Board and others. All other authors attest that they have no conflicts of interest in regard to the subject of this manuscript. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = apr,
day = "13",
doi = "10.1186/s13054-021-03465-0",
language = "English (US)",
volume = "25",
pages = "144",
journal = "Critical Care",
issn = "1364-8535",
publisher = "Springer Science + Business Media",
number = "1",
}